Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Cash (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Change in Cash data on record, last reported at $33.0 million in Q4 2025.

  • For Q4 2025, Change in Cash rose 274.0% year-over-year to $33.0 million; the TTM value through Dec 2025 reached $53.7 million, up 736.22%, while the annual FY2025 figure was $53.7 million, 736.22% up from the prior year.
  • Change in Cash reached $33.0 million in Q4 2025 per CTNM's latest filing, up from $21.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $61.0 million in Q2 2024 and bottomed at -$36.3 million in Q3 2024.
  • Average Change in Cash over 3 years is $5.8 million, with a median of $632500.0 recorded in 2024.
  • Peak YoY movement for Change in Cash: crashed 849.77% in 2024, then skyrocketed 274.0% in 2025.
  • A 3-year view of Change in Cash shows it stood at -$2.0 million in 2023, then plummeted by 849.77% to -$18.9 million in 2024, then surged by 274.0% to $33.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $33.0 million in Q4 2025, $21.8 million in Q3 2025, and -$1.7 million in Q2 2025.